Rodman & Renshaw Initiates Coverage On Heron Therapeutics with Buy Rating, Announces Price Target of $7
Portfolio Pulse from Benzinga Newsdesk
Rodman & Renshaw has initiated coverage on Heron Therapeutics (NASDAQ:HRTX) with a Buy rating and set a price target of $7.
June 13, 2024 | 5:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rodman & Renshaw has initiated coverage on Heron Therapeutics with a Buy rating and set a price target of $7.
The initiation of coverage with a Buy rating and a specific price target of $7 by Rodman & Renshaw is likely to positively impact Heron Therapeutics' stock price in the short term. Analyst ratings and price targets are significant indicators for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100